Лечение и препараты

HLB Secures FDA Approval for Bile Duct Cancer Drug… Liver Cancer Drug Resubmission Imminent

HLB Secures FDA Approval for Bile Duct Cancer Drug… Liver Cancer Drug Resubmission Imminent finance.biggo.com

Ученые нашли способ продлить эффект терапии при раке поджелудочной железы

Ученые нашли способ продлить эффект терапии при раке поджелудочной железы socportal.info

Pirtobrutinib Earns Approval in China for CLL/SLL Across All Therapy Lines

Siemens Healthineers Launches Accela Radiotherapy System With 60-Second SBRT Capability

Siemens Healthineers Launches Accela Radiotherapy System With 60-Second SBRT Capability Pulse 2.0

В Рязани пациента вылечили от рака без операций и химиотерапии

В Рязани пациента вылечили от рака без операций и химиотерапии 62ИНФО

MSD и Daiichi отозвали заявку на ускоренную регистрацию в США второй совместной терапии рака

MSD и Daiichi отозвали заявку на ускоренную регистрацию в США второй совместной терапии рака gxpnews.net

Применение «холодового шлема» предотвращает облысение у 67% онкопациентов при химиотерапии

Применение «холодового шлема» предотвращает облысение у 67% онкопациентов при химиотерапии ФармМедПром

HLB Wins FDA Approval for Acquired Bile Duct Cancer Drug

HLB Wins FDA Approval for Acquired Bile Duct Cancer Drug 조선일보

FDA Approves New First-Line Treatment Options for HER2-Positive AdvancedGastric and GEJ Cancer

FDA Approves New First-Line Treatment Options for HER2-Positive AdvancedGastric and GEJ Cancer news.cancerconnect.com

Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM

Tailored ACT+ therapy helps cancer survivors reconnect with valued living | Newswise

Tailored ACT+ therapy helps cancer survivors reconnect with valued living | Newswise Newswise

Beyond Surgery: Does Adjuvant Therapy Still Add Value for Patients With Pancreatic Cancer After Neoadjuvant Treatment?

Beyond Surgery: Does Adjuvant Therapy Still Add Value for Patients With Pancreatic Cancer After Neoadjuvant Treatment? Springer Nature Link

KEYNOTE-859 4.5-Year Follow-Up: Pembrolizumab Plus Chemotherapy in HER2-Negative Gastric/GEJ Cancer

KEYNOTE-859 4.5-Year Follow-Up: Pembrolizumab Plus Chemotherapy in HER2-Negative Gastric/GEJ Cancer Oncodaily

Merck, Daiichi pull US application for second partnered cancer therapy

Merck, Daiichi pull US application for second partnered cancer therapy Y100 WNCY

Merck, Daiichi pull US application for second partnered cancer therapy

Merck, Daiichi pull US application for second partnered cancer therapy KSL.com